Gritstone Bio Total Assets 2017-2024 | GRTSQ
Gritstone Bio total assets from 2017 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Gritstone Bio Annual Total Assets
(Millions of US $) |
| 2023 |
$178 |
| 2022 |
$241 |
| 2021 |
$278 |
| 2020 |
$222 |
| 2019 |
$184 |
| 2018 |
$190 |
| 2017 |
$117 |
| 2016 |
$46 |
Gritstone Bio Quarterly Total Assets
(Millions of US $) |
| 2024-06-30 |
$143 |
| 2024-03-31 |
$137 |
| 2023-12-31 |
$178 |
| 2023-09-30 |
$187 |
| 2023-06-30 |
$223 |
| 2023-03-31 |
$210 |
| 2022-12-31 |
$241 |
| 2022-09-30 |
$205 |
| 2022-06-30 |
$214 |
| 2022-03-31 |
$243 |
| 2021-12-31 |
$278 |
| 2021-09-30 |
$271 |
| 2021-06-30 |
$224 |
| 2021-03-31 |
$247 |
| 2020-12-31 |
$222 |
| 2020-09-30 |
$123 |
| 2020-06-30 |
$146 |
| 2020-03-31 |
$163 |
| 2019-12-31 |
$184 |
| 2019-09-30 |
$209 |
| 2019-06-30 |
$228 |
| 2019-03-31 |
$175 |
| 2018-12-31 |
$190 |
| 2018-09-30 |
$113 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2016-12-31 |
$46 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
